here is two of probably a few articles to come based on this announcment

Botanix Pharmaceuticals plans new study into antimicrobial platform and BTX 1801

https://*********.com.au/botanix-pharmaceuticals-plans-new-study-antimicrobial-platform-btx-1801/

As a result of its studies and internal development, Botanix says its BTX 1801 product is “more effective than the market-leading decolonisation agent, mupirocin”, against antibiotic-resistant strains of MRSA.

“Given one in three people in the community carry staph and/or MRSA in their nose on average, this study population is ideal to establish proof of efficacy of BTX 1801, before moving into a pivotal clinical study involving patients undergoing surgery, for FDA registration,” the company said.

Final preparations for Botanix’ phase 2a study are now underway with Botanix confirming it expects to enrol its first participants in Q2 2020.

Botanix Pharmaceuticals Limited's (ASX:BOT) Profit Outlook

https://au.news.yahoo.com/botanix-pharmaceuticals-limiteds-asx-bot-223319277.html

One thing I’d like to point out is that BOT has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which typically has high debt relative to its equity. This means that BOT has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.